View Older Stories

Nov 29, 2022 04:05PM Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD

Nov 29, 2022 04:05PM Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD

Nov 22, 2022 04:05PM Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference

Nov 22, 2022 04:05PM Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference

Nov 14, 2022 06:10AM Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates

Nov 14, 2022 06:10AM Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates

Nov 14, 2022 06:02AM Lumos Pharma (LUMO) Reports Encouraging Interim Results from Two Phase 2 Trials of Oral LUM-201

Nov 14, 2022 06:00AM Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency

Nov 14, 2022 06:00AM Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency

Sep 26, 2022 04:05PM Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference

Sep 26, 2022 04:05PM Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference

Aug 31, 2022 09:00AM Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Aug 31, 2022 09:00AM Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Aug 16, 2022 07:30AM Lumos Pharma, Inc. (LUMO) Announces $3M Share Buyback

Aug 16, 2022 07:30AM Lumos Pharma Announces Share Repurchase Program

Aug 9, 2022 04:01PM Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates

Aug 9, 2022 04:01PM Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates

Jul 27, 2022 04:05PM Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022

Jul 27, 2022 04:05PM Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022

May 16, 2022 04:05PM Lumos Pharma to Participate in Upcoming Investor Conferences

May 16, 2022 04:05PM Lumos Pharma to Participate in Upcoming Investor Conferences

May 10, 2022 04:01PM Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates

May 10, 2022 04:01PM Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates

May 5, 2022 09:01AM Lumos Pharma, Inc. (LUMO) Enters Collaboration with Massachusetts General Hospital to Evaluate LUM-201

May 5, 2022 09:00AM Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

May 5, 2022 09:00AM Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

Apr 26, 2022 09:00AM Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022

Apr 26, 2022 09:00AM Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022

Apr 11, 2022 08:30AM Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD

Apr 11, 2022 08:30AM Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD

Mar 23, 2022 04:05PM Lumos Pharma to Participate in the Cantor Rare Disease Symposium

Mar 23, 2022 04:05PM Lumos Pharma to Participate in the Cantor Rare Disease Symposium

Mar 10, 2022 04:01PM Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials

Mar 10, 2022 04:01PM Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials

Mar 10, 2022 09:00AM Lumos Pharma to Participate in Upcoming Investor Conferences

Mar 10, 2022 09:00AM Lumos Pharma to Participate in Upcoming Investor Conferences

Feb 23, 2022 09:00AM Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022

Feb 23, 2022 09:00AM Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022

Jan 5, 2022 09:00AM Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Jan 5, 2022 09:00AM Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Nov 10, 2021 05:06PM Lumos Pharma to Participate in Upcoming Investor Conferences

Nov 10, 2021 05:06PM Lumos Pharma to Participate in Upcoming Investor Conferences

Nov 3, 2021 04:01PM Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates

Nov 3, 2021 04:01PM Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates

Oct 21, 2021 04:05PM Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

Oct 21, 2021 04:05PM Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

Sep 2, 2021 08:00AM Lumos Pharma to Participate in September Investor Conferences

Sep 2, 2021 08:00AM Lumos Pharma to Participate in September Investor Conferences

Aug 5, 2021 08:00AM Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

Aug 5, 2021 08:00AM Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

View Older Stories